Outcome of pulmonary multidrug-resistant tuberculosis: A 6-yr follow-up study

European Respiratory Journal

Volumn 28, Issue 5, 2006, Pages 980-985

  Chiang, C Y ^a   Enarson, D A ^a   Yu, M C ^b   Bai, K J ^b   Huang, R M ^c   Hsu, C J ^d   Suo, J ^d   Lin, T P ^d  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c Chest Hospital   (Taiwan)

^d National Tuberculosis Association   (Taiwan)

Author keywords

Death; Follow up; Multidrug resistant; Relapse; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; ENVIOMYCIN; ENVIOMYCIN PLUS KANAMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CONFIDENCE INTERVAL; CONVULSION; DEATH; DIZZINESS; DRUG FATALITY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RELAPSE; SKIN MANIFESTATION; SUICIDAL IDEATION; TAIWAN; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; DRUG EFFECT; MIDDLE AGED; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; RECURRENCE; RETROSPECTIVE STUDIES; TAIWAN; TUBERCULOSIS, PULMONARY;

EID: 33847382372     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00125705     Document Type: Article

References (34)

1. Schaaf HS, Botha P, Gie RP, et al. The 5-year outcome of multidrug resistant tuberculosis patients in the Cape Province of South Africa. Trop Med Intern Health 1996; 1: 718-722.
2. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
3. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. Treatment outcomes in 6 countries. JAMA 2000; 283: 2537-2545.
4. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
5. Crofton J, Chaulet P, Maher D, et al. Guidelines for the management of drug-resistant tuberculosis. Geneva, World Health Organization, 1996; pp.1-40.
6. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
7. Park SK, Kim CT, Song SD. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. Int J Tuberc Lung Dis 1998; 2: 877-884.
8. Tahaoglu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
9. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/ levofloxacin-containing regimens. Chest 2000; 117: 744-751.
10. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
11. Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 2001; 5: 1129-1136.
12. Flament-Saillour M, Robert J, Jarlier V, Grosset J. Outcome of multi-drug-resistant tuberculosis in France. A nation-wide case-control study. Am J Respir Crit Care Med 1999; 160: 587-593.
13. Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 2004; 8: 361-368.
14. Van Deun A, Hamid Salim MA, Kumar Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8: 560-567.
15. Suárez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-1989.
16. Chiang C-Y, Enarson DA, Yang S-L, Suo J, Lin T-P. The impact of national health insurance on the notification of tuberculosis in Taiwan. Int J Tuberc Lung Dis 2002; 6: 974-979.
17. Suo J, Yu M-C, Lee C-N, Chiang C-Y, Lin T-P. Treatment of multidrug-resistant tuberculosis in Taiwan. Chemotherapy 1996; 42: Suppl. 3, 20-23.
18. Chiang C-Y, Hsu C-J, Huang R-M, Lin T-P, Luh K-T. Antituberculosis drug resistance among retreatment tuberculosis patients in a referral center in Taipei. J Formos Med Assoc 2004; 103: 411-415.
19. Maranetra KN. Quinolones and multidrug-resistant tuberculosis. Chemotherapy 1999; 45: Suppl. 2, 12-18.
20. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124; 1476-1481.
21. Mangunnegoro H, Hudoyo A. Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia. Chemotherapy 1999; 45: Suppl. 2, 19-25.
22. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3:432-442.
23. Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17: 169-173.
24. Rodríguez JC, Cebrián L, López M, Ruiz M, Jiménez I, Royo G. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004; 53: 441-444.
25. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 1342-1345.
26. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426.
27. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170: 1131-1134.
28. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003; 47: 3117-3122.
29. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15: 66-70.
30. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338.
31. Grimaldo ER, Tupasi TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.
32. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
33. Chiang C-Y, Yu M-C, Bai K-J, Lin T-P, Lee Y-C. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int J Tuberc Lung Dis 2001; 5: 272-277.
34. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002; 6: 143-149.